分析阿帕替尼联合顺铂腹腔灌注治疗卵巢癌恶性腹腔积液的有效性

Efficacy of Apatinib Combined with Cisplatin Peritoneal Infusion in the Treatment of Malignant Peritoneal Effusion of Ovarian Cancer

目的:探究卵巢癌恶性腹腔积液患者应用阿帕替尼联合顺铂治疗的效果。方法:随机抽取笔者所在医院2018年1月-2019年1月进行治疗的卵巢癌恶性腹腔积液患者60例为研究对象,实施顺铂治疗的30例为对照组,实施阿帕替尼联合顺铂治疗的30例为研究组,对比两组治疗效果、治疗前后腹水VEGF及不良反应发生情况。结果:研究组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗前两组腹水VEGF比较,差异无统计学意义(P>0.05);治疗后两组腹水VEGF均较治疗前有所改善,且研究组较对照组改善更显著,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卵巢癌恶性腹腔积液患者应用阿帕替尼联合顺铂的治疗效果明显好于单独使用顺铂治疗,能够在提升治疗效果前提下确保治疗的安全性,值得推广应用。

Objective:To explore the efficacy of Apatinib combined with Cisplatin in the treatment of patients with malignant peritoneal effusion of ovarian cancer.Method:A total of 60 patients with malignant peritoneal effusion of ovarian cancer treated in our hospital from January 2018 to January 2019 were randomly selected as the research object.30 patients were treated with Aisplatin as control group,and 30 patients treated with Apatinib combined with Cisplatin as the research group,The therapeutic effect,ascites VEGF and adverse reactions before and after the treatment were compared between the two groups.Result:The total effective rate of the research group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in ascites VEGF between the two groups before treatment(P>0.05).After treatment,the improvement of ascites VEGF in both groups was better than that before treatment,and the improvement in the research group was more significant than that in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The efficacy of Apatinib combined with Cisplatin in patients with malignant peritoneal effusion of ovarian cancer is significantly better than that of Cisplatin alone,which can ensure the safety of treatment under the premise of improving the therapeutic effect,and is worthy of promotion and application.